Thu, May 8, 11:14 AM (5 days ago)
**Q32 Bio Inc. (QTTB) Q1 2025 Financial Summary** **Financial Health:** - **Cash Position:** $65.5 million in cash and cash equivalents as of March 31, 2025. - **Liquidity:** Estimated to fund operations to the second half of 2026. - **Operating Expenses:** $12.2 million for Q1 2025, primarily research and development. **Performance Metrics:** - **Revenue:** No product sales revenue; reliance on funding and collaborations. - **Net Loss:** $11.0 million for Q1 2025, compared to a gain of $1.0 million in Q1 2024 due to a change in fair value of convertible notes. - **Research & Development (R&D) Expenses:** $7.1 million for Q1 2025, down from $9.8 million in Q1 2024. - **General & Administrative (G&A) Expenses:** $5.1 million for Q1 2025, stable compared to Q1 2024. **Earnings Changes:** - **Q1 2025 vs. Q1 2024:** Decrease in net loss by $12.0 million due to higher operating expenses and lower other income. - **Year-over-Year Trends:** Significant fluctuations in net loss and operating expenses. **Quarterly Performance Discussion:** - **Operating Expenses:** Decrease in R&D expenses due to reduced clinical spend and discontinuation of ADX-097 trial. - **Other Income (Expense):** Increase due to change in fair value of CVR liability and higher interest income. - **Cash Flow:** Negative cash flow from operations, primarily used for R&D activities. **Trends & Uncertainties:** - **Funding Requirements:** Dependence on additional capital to advance programs and commercialization. - **Regulatory Approvals:** Uncertainty in obtaining and maintaining regulatory approvals. - **Competitive Landscape:** Competition from other biotech and pharmaceutical companies. **Future Operations Impact:** - **Strategic Refocus:** Focus on bempikibart for alopecia areata treatment. - **Collaborations:** Potential for future collaborations to advance product candidates. - **Financial Projections:** Estimated cash runway to the second half of 2026, subject to uncertainties.